title: [Effect of Cancer Symptoms and Fatigue on Chemotherapy-related Cognitive Impairment and Depression in People with Gastrointestinal Cancer].
abstract: OBJECTIVE
  The purpose of this study was to test a hypothetical model of chemotherapy-related cognitive impairment (CRCI) and depression in people with gastrointestinal cancer.
  
  
  METHODS
  A purposive sample of 198 patients undergoing chemotherapy was recruited from November 2014 to July 2015. The instruments were Everyday Cognition (ECog), Hospital Anxiety Depression Scale (HADS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and M. D. Anderson Symptom Inventory-Gastrointestinal Cancer Module. Data were analyzed using descriptive statistics, correlation, and path analysis.
  
  
  RESULTS
  CRCI was directly affected by cancer symptoms (β=.19, p=.004) and fatigue (β=.56, p<.001)(R²=47.2%). Depression was directly affected by fatigue (β=.48, p<.001) and CRCI (β=.27, p<.001). However, The impact of cancer symptoms on depression was confirmed through the mediating effect of CRCI.
  
  
  CONCLUSIONS
  Results indicate that in patients with gastrointestinal cancer undergoing chemotherapy along with the direct physiologic effects (fatigue, symptoms) of cancer treatment may have altered cognitive function leading to depression.
authors.affiliation: Department of Nursing, Sahmyook University, Seoul, Korea.
authors.forename: Pok Ja
authors.initials: PJ
authors.lastname: Oh
authors.affiliation: Department of Nursing, Sahmyook University, Seoul, Korea. jrwin@naver.com.
authors.forename: Jung Ran
authors.initials: JR
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001007:Anxiety; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D060825:Cognitive Dysfunction / Q000209:etiology*; D003863:Depression / Q000209:etiology*; D004359:Drug Therapy, Combination; D005221:Fatigue; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008568:Memory; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D014175:Translating
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin
keywords: Depression; Fatigue; Mild cognitive impairment; Neoplasm